Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Signifor
(United States) [Available] ,Signifor LAR
(United States) [Available]Synonyms :
pasireotide
Class :
Antineoplastic agents & Somatostatin analog
Brand Name :
Signifor
(United States) [Available] ,Signifor LAR
(United States) [Available]Synonyms :
pasireotide
Class :
Antineoplastic agents & Somatostatin analog
Dosage Forms & Strengths
Solution, Subcutaneous (as diaspartate) (SC):
0.3 mg/ml (1ml)
0.6 mg/ml (1ml)
0.9 mg/ml (1ml)
Suspension, Intramuscular (as pamoate) (IM):
10mg/vial
30mg/vial
20mg/vial
40mg/vial
60mg/vial
Note: Monitor patients with diabetes mellitus and optimize antidiabetic therapy prior to initiating therapy. Treat the patients with hypokalemia and hypomagnesemia before starting the therapy.
Initial IM dose:
40
mg
once every 4 weeks (dose can be adjusted according to levels of growth hormone to 60 mg once every 4 weeks after >3 months if levels are normalized. Decrease the dose to 20 mg if adverse effects occur.)
Do not administer missed dose 2 weeks prior to the next dose.
Initial SC:
0.6 - 0.9
mg
twice a day
Dose adjustment: Increase the dose in increments of 0.3 mg twice a day every 3 months depending on the normalization of urinary-free cortisol levels
Decrease the dose by 0.3 mg if an adverse reaction occurs
Maintenance dose SC: 0.3 to 0.9 mg twice a day
Initial IM: 10 mg once every 4 weeks
Dose adjustment: Monitor for 24-hour UFC levels, if not normalized increase the dose maximum up to 40 mg once every 4 weeks
Discontinue the therapy if adverse reactions occur
Do not administer missed dose 2 weeks prior to the next dose
Dose Adjustments
For Hepatotoxicity:
Moderate hepatotoxicity for IM dose: Initially 20 mg once every 4 weeks and maintain not more than 40 mg once every 4 weeks
Severe hepatic impairment for IM dose: Discontinue temporarily
Moderate hepatotoxicity for SC: initial 0.3 mg twice a day and maintain 0.6 mg twice a day
Severe hepatic impairment for SC dose: Discontinue temporarily
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
QTc interval is increased both by lenvatinib and pasireotide
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
It may diminish the effects when combined with copper CU 64 dotatate by the receptor binding mechanism
pasireotide exerts its influence on gallium ga 68 dotatate by engaging in receptor binding competition, thereby diminishing its effects
Actions and Spectrum:
Actions:
Pasireotide, a synthetic polypeptide like somatostatin, effectively blocks the release of growth hormone, insulin, glucagon, and other digestive hormones.
Spectrum:
Pasireotide is a stable cyclohexapeptide with high binding affinity to SSTR1 and SSTR5, reducing IGF-I and GH levels in acromegaly patients more effectively than octreotide or lanreotide.
Frequency defined
>10%
Peripheral edema
Alopecia
Diabetes Mellitus
Abdominal distension
Decreased appetite
1%-10%
Prolonged QT interval on ECG
Sinus brady cardia
Pruritis
Hypokalemia
Hypothyroidism
Weight loss
Cholecystitis
Anemia
Dizziness
<1%
Diabetic ketoacidosis
Bradycardia
Cholangitis
Increased serum bilirubin
Black box warning:
None
Contraindication/Caution:
Contraindications include hypersensitivity to few drugs, and potential risk of cholelithiasis.
Pregnancy and Breastfeeding
Pregnancy/Lactation
Pregnancy consideration: Not assigned
Lactation:
Excretion of drug into human breast milk is unknown.
Pregnancy category:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
Pasireotide is a synthetic protein which is mainly used in cushing syndrome.
Pharmacodynamics:
It activates somatostatin receptors with high binding affinity and inhibits ACTH secretion and reduces cortisol levels in Cushing’s disease patients.
Pharmacokinetics:
Absorption
This drug absorbed rapidly into the bloodstream.
Distribution
It is widely distributed inside the body and have high binding affinity.
Metabolism
This undergoes liver enzymatic metabolism.
Excretion and Elimination
The body excretes through urine and feces.
Administration:
It is mainly adminstered through subcutaneously.
Generic Name: pasireotide
Pronounced: pas-i-REE-oh-tide
Why do we use pasireotide?
Pasireotide injection is prescribed for adults with Cushing’s disease who are not candidates for surgery or whose surgery was unsuccessful. It is also used to manage acromegaly in patients who are unable to undergo surgical treatment. This medication, marketed under the brand name Signifor®, can only be obtained with a doctor’s prescription.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
